Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03907527 · ClinicalTrials.gov registry record · Phase 1
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase 1 study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma, sponsored by Precigen.
- Active
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
- 2
- Study locations
NCT03907527 is a Phase 1 study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma that is active but no longer recruiting, run by Precigen. The registered enrollment target is 71 participants, below the 122-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (42% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03907527, a Phase 1 study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma, is active but no longer recruiting, sponsored by Precigen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen, Inc.) in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body, that has come back and is resistant to platinum chemotherapy. Autologous CAR T cells are modified immune cells that have been engineered in the laboratory to specifically target a protein found on tumor cells and kill them.
Conditions Studied
Interventions
- BIOLOGICAL PRGN-3005 UltraCAR-T cells
Study Locations (2)
Maryland
- National Institutes of Health (NIH) - Bethesda
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2028-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03907527
The ClinicalTrials.gov registry entry for NCT03907527 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 122-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (42% lower). The listed sponsor is Precigen, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Ovarian Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which PRGN-3005 UltraCAR-T cells is the first listed.
NCT03907527 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Washington.
Frequently Asked Questions
What is clinical trial NCT03907527 about?
NCT03907527 is a clinical study titled "Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer". This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen, Inc.) in treating patients with ovarian, fallopian tube, or primary perit...
What is the current status of trial NCT03907527?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2019-04-30. Estimated completion is 2028-11-15.
What conditions does trial NCT03907527 study?
This clinical trial studies the following conditions: Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma.
What interventions are being tested in trial NCT03907527?
The interventions under investigation include: PRGN-3005 UltraCAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03907527?
This trial is sponsored by Precigen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03907527 being conducted?
This trial has 2 study locations across Maryland, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
RECRUITING · Phase 1
-
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
RECRUITING · Phase 1
-
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
RECRUITING · Phase 1
-
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
RECRUITING · Phase 1
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Recurrent Ovarian Carcinoma
All registered trials for this condition
Recurrent Fallopian Tube Carcinoma
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.